A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRα), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the safety and tolerability of MEDI-575 and to determine the maximum tolerated dose in this subject population.
30 days after the last dose of MEDI-575.
Robert Sikorski, M.D.
United States: Food and Drug Administration
|Research Site||Las Vegas, Nevada|
|Research Center||Arlington, Texas 76012|
|Research Center||Denver, Colorado 80218|
|Research Center||Indianapolis, Indiana 46219|
|Research Center||Norfolk, Virginia 23502|